As we enter 2026, we take a moment to reflect on the significant achievements of 2025. With the strength and support of our parent company, Hetero, Camber successfully launched a broad range of high-quality generic medications, including multiple specialty and oncology products—further reinforcing our commitment to access, affordability, and reliability.
Key achievements in 2025 include:
- Expanded the Camber team by 12%
- Filed 40 ANDAs and received 43 ANDA approvals
- Participated in more than 60 trade events and industry conferences
- Executed a highly successful Day-1 launch of Eltrombopag
“These accomplishments reflect the strength of our organization, the dedication of our team, and the ongoing commitment of our parent company, Hetero, to develop and deliver high-quality, life-saving medicines to the U.S. market,” said Kon Ostaficiuk, President of Camber Pharmaceuticals. “We remain focused on exceeding expectations every day—for our patients, customers, partners, and associates.”
Looking ahead to 2026, Camber is well-positioned for continued growth. Our rapidly expanding portfolio of specialty and generic oncology products is expected to deliver 35+ new product launches, supported by a disciplined and robust pipeline. Camber anticipates 43 ANDA approvals and 40 ANDA filings in the year ahead.
“Our success is driven by the dedication of our associates, the trust of our customers, and the strong partnerships we’ve built across the industry,” added Scott Hettenhausen, Vice President of Sales. “With this foundation in place, we are confident that 2026 will be another impactful year for Camber.”
2025 Product Launches:
- Abacavir and Lamivudine Tablets
- Amlodipine and Olmesartan Medoxomil Tablets
- Bexarotene Capsules
- Bumetanide Injection, USP
- Bupivacaine HCl, USP, Injection
- Carbidopa and Levodopa Tablets
- Chlorpromazine HCl Injection
- Chlorzoxazone Tablets
- Dabigatran Tablets
- Darunavir Tablets
- Eletriptan HBR Tablets
- Eltrombopag for Oral Suspension
- Eltrombopag Tablets
- Eslicarbazepine Acetate Tablets
- Furosemide Injection
- Imatinib Mesylate Tablets
- Indomethacin Suppositories
- Lubiprostone Capsules
- Lurasidone HCl Tablets
- Magnesium Sulfate Injection USP
- Metformin HCl Oral Solution
- Mycophenolate Mofetil Capsules
- Mycophenolate Mofetil Tablets
- Nilotinib Capsules
- Olmesartan Medoxomil Tablets
- Phenylephrine HCl SDV Injection
- Posaconazole Injection
- Prucalopride Tablets
- Sacubitril and Valsartan Tablets
- Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Packet for Oral Solution
- Spironolactone Oral Suspension
- Temozolomide Capsules
- Voriconazole Injection
